Medicare Part D prescription drug plan sponsors are mandated to have MTM programs in place.
“People not taking their medicine as directed is a major cause of hospitalization, poor health care outcomes and increased overall health care costs,” Prime Therapeutics Principal Health Outcomes Researcher Cathy Starner said. “Finding that Prime’s MTM program yields positive results for our members provides evidence our approach works. We encourage our health plans’ members to participate in MTM and it helps the plans achieve the best star rating possible. It is a win-win scenario.”
For the study, researchers analyzed the medication-taking habits of 106,915 Prime Therapeutics' Medicare members.
The study's findings were presented at the Academy of Managed Care Pharmacy Nexus event that wrapped up Thursday in Orlando, Florida.
For more information on the study, visit www.primetherapeutics.com.
Prime Therapeutics is an independent pharmacy benefit manager.